High-dose insulin therapy: is it time for U-500 insulin? von Lane, Wendy S, Cochran, Elaine K, Jackson, Jeffrey A, Scism-Bacon, Jamie L, Corey, Ilene B, Hirsch, Irl B, Skyler, Jay S

Volltext

Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve contro... von Miser, William F., MD, MA, Arakaki, Richard, MD, Jiang, Honghua, PhD, Scism-Bacon, Jamie, PhD, Anderson, Pamela W., MD, Fahrbach, Jessie L., MD

Volltext

Effect of Growth Hormone Replacement on BMD in Adult‐Onset Growth Hormone Deficiency von Snyder, Peter J, Biller, Beverly MK, Zagar, Anthony, Jackson, Ivor, Arafah, Baha M, Nippoldt, Todd B, Cook, David M, Mooradian, Arshag D, Kwan, Anita, Scism‐Bacon, Jamie, Chipman, John J, Hartman, Mark L

Volltext

Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents von Rosenstock, Julio, Ahmann, Andrew J., Colon, Gildred, Scism-Bacon, Jamie, Jiang, Honghua, Martin, Sherry

Volltext

Safety of exenatide once weekly for 52 weeks in J apanese patients with type 2 diabetes mellitus von Onishi, Yukiko, Koshiyama, Hiroyuki, Imaoka, Takeshi, Haber, Harry, Scism‐Bacon, Jamie, Boardman, Marilyn K

Volltext

Efficacy and Safety of Dulaglutide Versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1) von Wysham, Carol, Blevins, Thomas, Arakaki, Richard, Colon, Gildred, Garcia, Pedro, Atisso, Charles, Kuhstoss, Debra, Scism-Bacon, Jamie, Lakshmanan, Mark

Volltext

1.2 Efficacy and Safety of Dulaglutide versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1) (66-OR) von Wysham, Carol H., Blevins, Thomas C., Arakaki, Richard, Colon, Gildred, Garcia, Pedro, Atisso, Charles, Kuhstoss, Debra, Scism-Bacon, Jamie, Lakshmanan, Mark

Volltext